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Abstract
	 Background:	The	present	study	investigated	the	effects	of	Quercus infectoria (QI)	gall	extract	
on	the	proliferation,	alkaline	phosphatase	(ALP),	osteocalcin,	and	the	morphology	of	a	human	fetal	
osteoblast	cell	line	(hFOB	1.19).
	 Methods:	The	cells	were	cultured	in	Dulbecco’s	modified	eagle	medium	F12	supplemented	
with	a	 10%	 fetal	bovine	serum,	a	 1%	penicillin/streptomycin	and	were	 treated	with	QI	at	 various	
concentrations	(0.1	to	99.0	µg/mL)	for	72	hours.	The	levels	of	ALP	and	osteocalcin	were	measured	at	
day	1,	3,	7,	10,	and	14	and	were	compared	among	the	negative	control,	pamidronate	and	QI	groups.
	 Results:	The	median	effective	concentration	(EC50)	of	hFOB	1.19	treated	with	QI	was	10.30	
µg/mL.	This	concentration	was	more	effective	compared	to	the	control	drug,	pamidronate	(EC50	at	
16.09	µg/mL).	The	ALP	and	osteocalcin	levels	of	hFOB	1.19	treated	with	QI	from	day	7	and	onwards	
were	significantly	increased	in	a	time	and	concentration-dependent	manner.	Interestingly,	from	day	
7	until	day	14,	the	ALP	and	osteocalcin	levels	were	highest	in	the	cells	treated	with	QI	compared	to	
the	other	two	groups.	The	morphology	of	cells	treated	with	QI	was	uniformly	elongated,	higher	in	
number	and	over-confluent.
	 Conclusion: After	treatment	with	QI,	cell	proliferation	enhanced	and	ALP	and	osteocalcin	
levels	increased.
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Introduction
 The human skeleton is an important 
structural support that has its own homeostatic 
activity to maintain its structural integrity. This 
homeostatic activity is carried out by osteoblasts 
and osteoclasts via a process termed “bone 
remodeling.” In a healthy adult, under normal 
circumstances, osteoblast, and osteoclast activity 
is a balanced process where bone resorption 
is always followed by an equal degree of bone 
formation. This process is indicated by the 
expression of various phenotypic markers such 
as alkaline phosphatase (ALP) and osteocalcin 
(1). Osteocalcin is produced by osteoblasts and 
is a sensitive marker of bone formation (2). ALP 
has become the most clinically relevant enzyme in 
the diagnosis of bone disease (3) and is routinely 
used in in vitro experiments as a relative marker 
of osteoblastic differentiation (4,5). Other than 
normal physiological bone growth, bone-specific 
ALP (BAP) activity also correlates with bone 
formation rates in metabolic diseases of the 
bone (6). The association between BAP and bone 
loss is equivalent between bone mineral density 
(BMD) and fractures, and suggests the marker 
can play a valuable role in risk assessment (7). 
Any imbalance in the activity of osteoblasts and 
osteoclasts often leads to pathological situations 
such as osteoporosis or osteopetrosis. 
 Osteoporosis is a metabolic bone disease 
characterized by low bone mass and micro-
architectural deterioration of bone tissue, and it 
is a major public health problem because of its 
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association with age-related fractures (8). The 
occurrence of osteoporosis increases with age, 
when bone mass starts to decrease at about age 
35 and continually decreases thereafter in both 
men and women. Generally, white or Asian post-
menopausal women with thin body frames are 
considered at risk for developing osteoporosis; 
additional factors include a lack of estrogen for 
a significant portion of a woman's lifetime, a 
sustained lack of calcium in the diet (or a poor 
absorption  of  calcium),  inadequate exercise, a 
family history  of osteoporosis,  excessive  alcohol 
use  and  smoking (9). 
 Treatments for osteoporosis are designed to 
reduce bone loss, increase bone formation or both. 
The treatment consists of dietary and lifestyle 
changes along with pharmacologic intervention. 
Hormone replacement therapy (HRT) has been 
shown to be effective in preventing osteoporosis. 
The effective treatment options for women 
who have been diagnosed with the disease are 
bisphosphonates, calcitonin, and hormone 
replacement therapy (HRT) (10). However, the 
risks of long-term treatment of with these drugs 
are undesirable in most patients. For example, 
the use of HRT is associated with increased risks 
of ovarian cancer (11), endometrial cancer (12), 
stroke (13), and venous thromboembolism (14).  
 Musculoskeletal problems can be effectively 
treated but many cannot be reversed, so early 
treatment is important to get the best outcome. 
Presently, many people turn to natural products 
to treat diseases such as cancer and osteoporosis. 
Thus, studying these products in a scientific 
manner to determine their efficacy and safety is 
important. These natural products can then be 
developed into clinically acceptable medications 
for future therapeutic use. 
 Quercus infectoria (QI) Olivier (Fagaceae) 
is a small tree widely distributed in Greece, Asia 
Minor, and Iran. The tree bears galls that emerge 
on its young branches due to the attack of gall 
wasps, Cypnis gallae-tincotoriae (15). The galls 
are mixed with other herbs and ingested by post-
partum women as a folk remedy to restore the 
elasticity of the uterine wall (16). QI galls have 
been proven to have an astringent effect as well 
as anti-diabetic, anti-tremorine, local anaesthetic, 
anti-pyretic, anti-inflammatory, antiviral, 
antibacterial, and antioxidant properties (17–20). 
The pharmacological properties of QI gall extract 
are reportedly due to the presence polyphenols. 
Additionally, the QI galls also contain calcium, 
phosphorus, potassium, magnesium, iron, 
manganese, zinc and nickel (21). These minerals, 
especially calcium and phosphorus, are essential 
for bone mineralisation and may be beneficial to 
prevent bone diseases like osteoporosis.
 Furthermore, QI galls also have plenty of 
phytochemicals that possess an anabolic effect 
on bone. The main phytochemicals found in QI 
galls are tannin (50–70%), gallic acid (2–4%), 
ellagic acid, starch, and sugar (22). Our pevious 
study by Rina et al. (23), found that water and 
ethanol extracts of QI contained substantial 
amounts of phenolic compounds [144.5 to 177.5 
mg phosphoenolpyruvate carboxylase (PEPC) 
/g MKE] but negligible amounts of flavanoids. 
Recently, Shrestha et a1. (2004), found that 
preliminary phytochemical screening of leaf galls 
of QI from water extract showed the presence 
of phenols, flavanoids, saponins, alkaloids, 
carbohydrates, and tannins (24). Tannin, which 
is a phenolic compound, can act directly on the 
bone (25) by modulating osteoblast proliferation, 
differentiation, and mineralisation (26). 
 Recently, we published a review paper (27) 
which concluded that QI might have a potential 
anabolic effect on osteoblast function and bone 
metabolism by upregulating the osteoblast 
markers [runx2, Osx, IGF-1, bone-specific 
alkaline phosphatase (BSAP), ALP, osteocalcin, 
bone mineral content (BMC), and BMD]. Thus, 
a laboratory study is needed to elucidate the 
exact mechanism of QI’s action on bone. In this 
present study, the effects of QI gall extract on the 
proliferative activity of a human fetal osteoblast 
cell line (hFOB 1.10 cells) was observed using an 
enzyme-linked immunosorbent assay (ELISA) 
and inverted microscopy.
Materials and Methods
Preparation of Quercus infectoria (QI) gall 
extract
 The Quercus infectoria (QI) gall was obtained 
from the local market. The QI galls were crushed 
and ground into powder form. The QI gall powder 
was then diluted in distilled water and extracted 
by refluxing in a water bath at 50 °C for 24 hours. 
The extract was filtered by using filter paper 
and concentrated by using a rotary evaporator 
(Heidolph Rotavac, Germany). The aqueous QI 
gall extract was lyophilised in a freeze-drier until 
it turned into powder; finally, it was stored at 
-20 °C until use.
Cell culture
Cell Revival and Subculture 
 Human osteoblast cell lines, hFOB 1.19 (CRL-
11372), were purchased from American Type Cell 
Culture, ATCC (Manassas, USA). The hFOB 1.19 
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cells were cultured in Dulbecco’s Modified Eagle 
Medium F-12, DMEM/F12 (Invitrogen GmBH, 
Germany) which was supplemented with 10% 
fetal bovine serum (FBS), (Invitrogen GmBH, 
Germany) and 1% penicillin/streptomycin 
(Invitrogen GmBH, Germany). The cells were 
incubated in a 5% CO2 37 °C humidified incubator 
(Sheldon, United States) and monitored closely 
for 24 hours. The aseptic work was maintained 
by using a laminar flow (ESC II Series, Germany) 
to avoid contamination of the cultured cells. The 
laminar flow was sterilised by switching on the 
ultraviolet (UV) (40-watt) germicidal tubes prior 
to work.
Proliferation assay
 The proliferation assay was done to 
determine the number of hFOB 1.19 cells treated 
with QI gall extract and pamidronate at days 1, 3, 
7, 10, and 14. The cells were plated at 5 × 103 cells/
well with a 100 uL culture medium per well in the 
96-well microtiter plate and left overnight prior to 
attachment. QI gall extract and pamidronate were 
added into each well at different concentrations 
and incubated at 5% CO2 in a 37 °C humidified 
incubator. The cells were trypsinised with 100 uL 
trypsin/EDTA and incubated for 3 minutes for 
the cells to detach. Then, an inverted microscope 
was used to view the cells and confirm that a 
90% detachment had occurred. In order to stop 
the trypsinisation process, a 200 uL of culture 
medium was added and resuspended as well. 
Automated cell counting was carried out using the 
Countess Automated Cell Counter (Invitrogen, 
USA), and the graph of percentage of proliferation 
versus time (days) was plotted by using GraphPad 
Prism 5.0 (GraphPad Software Inc., USA).
Cell treatment
 QI gall extract and pamidronate treatments 
were used (Toronto Research Chemicals, Canada). 
QI gall extract was diluted in dimethyl sulphate 
(DMSO) (Fisher Scientific, USA). Pamidronate 
was used as a positive control whereas the cells 
treated with a complete medium only was used 
as the negative control. The treated cells were 
incubated for 72 hours in the 37 °C humidified 
incubator and supplemented with 5% CO2. The 
tests were conducted in triplicate and repeated at 
least three times.
Cell viability and half maximal effective 
concentration (EC50) determination
 In order to determine cell viability, 
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide (MTT) method was 
used after the cultured cells were about 80% 
confluent. In this test, yellow 3-(4, 5-dimethyl-
2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium 
bromide was reduced to a purple formazan. The 
treated and untreated cells were incubated with 
a 100 uL culture medium and 15 uL MTT for 
4 hours in the incubator (Sheldon, US). After that, 
100 uL of stop solution was added into each well 
and incubated for 1 hour. The optical density was 
will determined at 570 nm by using a microtiter 
plate reader (VersaMax, US). The intensity of 
the wavelength absorbed was proportional to the 
percentage of viable cells present in the wells. 
The graph of the percentage of viable cells versus 
log10 concentration (µg/mL) of QI gall extract 
was plotted using GraphPad Prism 5.0. From the 
graph, the half maximal effective concentration 
(EC50) was determined, and this concentration 
was used to treat the cells in order to study the cell 
morphology as well as determining the alkaline 
phosphatase (ALP) activity and the osteocalcin 
level.
 The percentage of cell viability of the 
treated cells as compared to the control cells was 
expressed as the percentage of viable cells. Viable 
cells will be determined from the formula below:   
% of viable cells (MTT) = OD sample × 100%
OD control
OD samples = Optical density of treatment 
samples, and OD value = Optical density of 
control.
Cell morphology by inverted microscopy
 The cell morphology of hFOB 1.19 was 
observed by using an inverted microscope, Leica 
DM IL (Wetzlar, Germany). The flask containing 
the cells were obtained from the incubator and 
placed on the microscope stage and focused at 4× 
magnification. For a closer or larger view of the 
cells, the magnification was changed to 10×, 22×, 
40×, and 100×. 
Determination of functional activity
Quantification	of	ALP	activity	in	the	
medium	by	ELISA
 The ALP activity of hFOB 1.19 treated with 
QI gall extract and pamidronate was detected 
through the hydrolysis of p-nitrophenyl 
phosphate (substrate) into p-nitrophenol at 
37 °C with pH 10.3. This was achieved by using 
ALP ELISA-test kit (Randox, UK). The cells were 
plated in a 96-well microtiter plate at 5 × 103 cells/
well with 115 µL culture medium per well. After 24 
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hours, the cells were treated with QI gall extract 
and pamidronate. Then, the treated cells were 
incubated following the incubation time (days 1, 
3, 7, 10, and 14) in the 37 °C humidified incubator 
supplemented with 5% CO2. The ALP activities 
were measured using an ELISA plate reader 
(VersaMax, US) at 405 nm wavelength. 
		
Quantification of osteocalcin level in the medium 
by ELISA
 An osteocalcin ELISA-test kit (BMAssay, US) 
was used to detect osteocalcin levels. The treated 
cells were incubated following the incubation time 
(days 1, 3, 7, 10, and 14) in the 37 °C humidified 
incubator at 5% CO2. The cells were retrieved by 
trypsinisation and centrifuged to obtain the cell 
pellet. The cell pellet was resuspended in 1 mL 
serum-free medium (DMEM/F12) and stored in 
-80 °C until used. The serum-free medium was 
used here instead of a complete culture medium 
because the presence of serum (FBS) in the 
culture medium may lead to false positive results. 
For days 3, 7, 10, and 14, the cell suspensions 
were stored in –80 °C until used. The osteocalcin 
levels were measured using an ELISA plate reader 
(VersaMax, US) at 450 nm.
Statistical analysis
 Results were expressed as mean values ± 
standard deviation (SD). Data were analysed with 
paired t test for cell viability or EC50 determination 
by using GraphPad Prism 5.0. In addition, data 
analysis for the results of proliferation activity, 
alkaline phosphatase (ALP) and osteocalcin 
were performed using the Statistical Package 
of Social Sciences (SPSS) Software, version 20. 
The Shapiro-Wilk test was used for normality 
checking. The statistical significance of differences 
was determined using one-way ANOVA followed 
by Tukey HSD test as a post-hoc. The result was 
considered to be statistically significant for a 
P value of < 0.05.
Results
Half maximal effective concentration (EC50) 
of Quercus infectoria (QI) gall extract and 
pamidronate treatments for hFOB 1.19 cells 
 Our results showed that the EC50 for QI 
gall extract was 10.30 µg/mL, whereas the EC50 
for pamidronate was 16.09 µg/mL (Figure 
1). The concentration for QI gall extract was 
more effective compared to pamidronate. This 
indicated that lower concentrations of QI gall 
extract are required to enhance the proliferation 
of osteoblasts (hFOB 1.19 cells) as compared to 
pamidronate, which is a well-known osteoporotic 
drug. 
 The EC50 for both treatments were then used 
to treat hFOB 1.19 cells to observe the pattern of 
cell proliferation during 14 days of incubation. 
Figure	 1: Graph of percentage of cell viability 
versus log final concentration of 
pamidronate and Quercus infectoria 
(QI) gall extract. Paired t test 
was significant (P < 0.05).  EC50 
values were calculated by using 
dose response stimulation curve in 
GraphPad Prism version 5.00 for 
Windows. The EC50 for QI gall extract 
was 10.30 µg/ml, lower than EC50 for 
pamidronate, 16.09 µg/mL.
Figure	 2: Bar chart for percentage of cell 
viability versus log final 
concentration of pamidronate and 
QI gall extract. Paired t test was 
significant (P < 0.05).
16 www.mjms.usm.my
Malays J Med Sci. Jan-Feb 2015; 22(1): 12-22
The graphs of proliferation versus the time in 
days were plotted to see the proliferation pattern. 
The result showed that the number of hFOB 1.19 
cells treated with both QI gall extract as well as 
pamidronate were increased in a dose-dependent 
manner (Figure 2). 
Morphology of hFOB 1.19 cells by inverted 
microscope
 The morphology of the hFOB 1.19 cells after 
seeding appeared to be rounded because they are 
suspended in the medium and not yet attached 
to the surface (Fugure 3a). Healthy cultured 
cells usually take about 24 hours to attach to the 
surface and live. After incubation for 24 hours, 
they appeared flat, elongated, and expanded, 
which indicated that they were already attached 
to the surface (Figure 3b).
 On day 3, of the incubation period, the hFOB 
1.19 cells that were treated with QI gall extract 
were observed to have a uniformly elongated 
shape and overlapped on each other (Figure 3c). 
This indicated that the cells became confluent 
on the third day of treatment. Meanwhile, hFOB 
1.19 cells treated with pamidronate and control 
cells (without treatment) on the third day of the 
incubation period were observed to be elongated, 
sparsely distributed and less dense (Figure 3d,3e). 
 In addition, the existence of the spaces in 
between the hFOB 1.19 cells indicated that on 
day 7, the cells treated with pamidronate and 
without treatment were proliferating at a slower 
rate as compared to the cells treated with QI gall 
extract (Figure 4a,4b,4c). After 10 days, the hFOB 
1.19 cells treated with QI gall extract were over-
confluent and overlapped on each other (Figure 
4d). Whereas, the condition of hFOB 1.19 cells 
treated with pamidronate were scattered, rounded 
and less dense (Figure 4e).  
 Until day 14, the hFOB 1.19 cells treated 
with QI gall extract were still alive and actively 
multiplying (Figure 5a). However, the cells treated 
with pamidronate and without treatment were 
decreased in number, and many of them were 
dead (Figure 5b,5c). Interestingly, the observation 
of the hFOB 1.19 cell morphology by inverted 
microscopy revealed that most of the hFOB 1.19 
cells treated with pamidronate were dead or had 
deteriorated at day 10 of the incubation period 
(Figure 4e). 
Proliferation Assay of hFOB 1.19 cells
 The cell (hFOB 1.19) number was compared 
among negative control, pamidronate and QI gall 
Figure	4: hFOB 1.19 cell line in 96-well microtiter plates viewed at 22× magnification using an inverted 
microscope. (a) Day 7, hFOB 1.19 cells treated with pamidronate. (b) Day 7, hFOB 1.19 control 
cells. (c) Day 7, hFOB 1.19 cells treated QI gall extract. (d) hFOB 1.19 cells treated with QI gall 
extract on day 10. (e) Day 10, cells treated with pamidronate.
Figure	3: hFOB 1.19 cells in 96-well microtiter plates viewed at 22× magnification using an inverted 
microscope. (a) The hFOB 1.19 cells after seeding. (b) Day 1 (after 24 hours incubation) before 
treatment. (c) Day 3, hFOB 1.19 cells treated with QI gall extract. (d) Day 3, hFOB 1.19 cells 
treated with pamidronate. (e) Day 3, hFOB 1.19 control cells (without treatment).
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extract after 1, 3, 7, 10, and 14 days of incubation. 
Figure 6 shows that the hFOB 1.19 cells in all the 
three groups were significantly increased with 
time (day 3 until day 14). Interestingly, from day 
3 onwards, the number of hFOB 1.19 cells were 
significantly higher in the QI gall extract group 
as compared to the other two groups. Moreover, 
from day 3 until day 14, the hFOB 1.19 cells were 
significantly lower in the pamidronate-treated 
group as compared to the negative control and 
QI-treated groups. 
Alkaline Phosphatase (ALP) activity of hFOB 
1.19 cells
 The ALP activities of the treated and untreated 
hFOB cells increased with time and peaked at day 
14. Figure 7 shows that the ALP activities in the 
hFOB 1.19 cells in both treated and untreated cells 
were significantly increased with a time course 
(day 7 until day 14). Subsequently, starting on day 
7 and onwards, the ALP activity in the hFOB 1.19 
cells treated with QI gall extract was significantly 
higher compared to the other two groups. On 
day 14, the highest activity for ALP in the QI gall 
extract treated cells was recorded as 41.70 U/L. 
Osteocalcin level of hFOB 1.19 cells
 The osteocalcin activities for QI gall extract 
treated hFOB 1.19 cells and untreated cells were 
increased in a time-dependent manner and peaked 
at day 14. Figure 8 shows that the osteocalcin 
levels in the hFOB 1.19 cells in all three groups 
increased gradually along the incubation period 
from day 3 to day 14. In addition, from day 3 until 
day 14, the osteocalcin levels in the hFOB 1.19 
cells treated with QI gall extract were significantly 
higher than in the other two groups. On day 14, 
Figure	5: hFOB 1.19 cell line in 96-well microtiter 
plates viewed at 22× magnification 
using an inverted microscope. (a) Day 
14, hFOB 1.19 cells treated with QI gall 
extract. (b) Day 14, cells treated with 
pamidronate. (c) Control cells (without 
treatment) on day 14.
Figure	 6: Cell number (×104) after 1, 3, 7, 10, 
and 14 days of incubation. The 
values of the bars represented mean 
± standard deviation (SD) of the 
three independent experiments. 
* Significant difference between the 
three groups within the same day 
(P < 0.05) by one-way ANOVA and 
Tukey’s test. Days that share the same 
letter showed a significant difference 
(within the same group) (P < 0.05) by 
one-way ANOVA and Tukey’s test.
Figure	 7: Alkaline phosphatase activity by 
hFOB 1.19 cells; untreated hFOB 
1.19 cells (control), hFOB 1.19 cells-
treated Quercus infectoria and hFOB 
1.19 cells-treated pamidronate after 
1, 3, 7, 10, and 14 days of incubation. 
The values of the bars represented 
mean (SD) of three independent 
experiments. * indicates significant 
difference between the three groups 
within the same day (P < 0.05) by 
one-way ANOVA and Tukey’s test. 
Days that share the same letter 
show a significant difference (within 
same group) (P < 0.05) by one-way 
ANOVA and Tukey’s test.
18 www.mjms.usm.my
Malays J Med Sci. Jan-Feb 2015; 22(1): 12-22
Figure	 8: Osteocalcin level of hFOB 1.19 cells; 
untreated hFOB 1.19 cells (control), 
hFOB 1.19 cells- treated Quercus 
infectoria and hFOB 1.19 cells- 
treated pamidronate after 1, 3, 7, 10, 
and 14 days of incubation. The values 
of the bars represented mean  (SD) of 
the three independent experiments. 
* Indicates significant difference 
compared to day one within the 
same group by one-way ANOVA and 
Tukey’s test. Days that share the same 
letter show a significant difference 
(within similar group) (P < 0.05) by 
one-way ANOVA and Tukey’s test.
the highest osteocalcin level in the QI gall treated 
cells was 3.43 ng/mL.
Discussion
 This study evaluated the effects of Quercus 
infectoria (QI) gall extract treatment on the 
biochemical analysis of bone formation markers 
(ALP and osteocalcin) and light microscopy on 
bone-forming cells by using a human osteoblast 
cell line (hFOB 1.19) model. Prior to observing 
the proliferative effects of the QI gall extract, 
we have to determine the half maximal effective 
concentration (EC50) of QI gall extract and 
pamidronate which was used as the positive 
control for this study. The percentage of hFOB 
1.19 cell viability increased in a concentration 
and time-dependent manner after treatment with 
QI gall extract and the anti-osteoporotic drug, 
pamidronate. 
 Interestingly, we have found that the EC50 of 
QI gall extract (10.30 µg/mL) needed to induce 
cell proliferation is lower than pamidronate 
(EC50 = 16.09 µg/mL). This finding showed 
that the proliferative activity of hFOB 1.19 cells 
were much greater when treated with QI gall 
extract, whereas the proliferative activity of 
hFOB 1.19 cells treated with pamidronate were 
not as effective as the QI gall extract. This may 
be due to the presence of polyphenols, the main 
phytochemical contained in the QI gall extract 
(28). Furthermore a previous study had shown 
that a polyphenolic phytoestrogen enhances 
proliferation and osteoblastic differentiation in 
human mesenchymal stem cells (29). 
 To support biochemical evidence, the 
histological study was done using an inverted 
microscope to evaluate the morphological 
changes of the hFOB 1.19 cells before and after 
treatment with the QI gall extract or pamidronate. 
Our biochemical data seemed to be congruent 
with the morphological study. Various types of 
cells have different morphological characteristics. 
The most important morphological characteristic 
of osteoblasts is that they are spindle-shaped 
and elongated with only slight areas of spreading 
at the end of long lamellipodia (30). However, 
the morphology of hFOB 1.19 cells was altered 
following treatment with QI gall extract and 
pamidronate. 
 The hFOB 1.19 cells that were treated 
with QI gall extract were observed to have a 
uniformly elongated shape, parallel orientation 
(31), and an overlap on each other due to rapid 
cell multiplication. On the other hand, the hFOB 
1.19 cells treated with pamidronate were observed 
to also have elongated shape but were sparsely 
distributed and less dense. The evaluation of 
cellular morphology by inverted microscopy 
revealed that the hFOB 1.19 cells treated with 
pamidronate were dead or deteriorated. This 
may be because long term use of pamidronate 
may reduce bone growth (32). Therefore, the 
histological study of the cells had proven the 
ability of QI gall extract to stimulate the hFOB 
1.19 cells’ multiplication and the morphological 
appearance was better than pamidronate. 
 As for further evidence of the proliferative 
effect of QI gall extract on hFOB 1.19 cells, the 
alkaline phosphatase (ALP) activity was measured 
by using ELISA method. The results showed an 
increase in ALP activity during the 14 days for 
both treatments. The hFOB 1.19 cells treated with 
QI gall extract showed higher activity of ALP as 
compared to the cells treated with pamidronate as 
well as untreated cells. This result was consistent 
with a study where ALP activity in hFOB/pvc 
cells was found to be significantly increased as 
a function of time in cultured cells (and peaked 
on day 12) (33). In addition, the ALP was 
upregulated and increased in the presence of QI 
gall extract just after 24 hours, and it continued 
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to have an almost sixfold increase on day 3 of 
incubation (0.85 U/L on day 1 and 5.05 U/L on 
day 3). From day 7 until day 14, the ALP activity 
in the hFOB 1.19 cells was significantly higher in 
the QI gall-treated group when compared with 
control groups. This condition was in line with 
a study done by Wanachewin et al. (34), where 
they found that the ALP activity of hFOB 1.19 cells 
significantly increased after 3, 7, and 14 days of 
sesamin treatment, while the ALP activity reached 
its highest levels on day 7 of the culture. Sesamin 
is a class of phytoestrogens isolated from the oil of 
sesame seeds (Sesamum indicum) and has been 
shown to exhibit a variety of properties (35). This 
result agreed with previous findings that ALP is 
most highly expressed during the onset of the 
mineralisation process which lasts for 7 days, and 
hFOB cell mineralisation begins to decrease by 
day 14 of the culture (36). 
 The osteocalcin level was measured by using 
the ELISA method on days 1, 3, 7, 10, and 14. After 
treatment with the QI gall extract, the osteocalcin 
levels gradually and persistently increased until 
day 14 of the incubation period. These results 
showed that the osteocalcin secretion increased 
fivefold on day 3 (0.16 ng/mL on day 1 and 
0.85 ng/mL on day 3). This data was similar to 
Hsu et al. (37), who reported that myricetin (a 
flavonoid compound in vegetables and fruits) 
caused a significant increase in osteocalcin and 
the ALP activity of both hFOB human osteoblasts 
and MG-63 (human osteosarcoma cell line). The 
expression or upregulation of osteocalcin by 
osteoblasts suggested that the osteoblastic cells 
had undergone maturation (38). Our results 
showed that osteocalcin secretion was high in 
the presence of QI gall extract, and that implied 
that the extract promoted the differentiation and 
maturation of hFOB 1.19 cells. 
 Our findings  indicated that QI gall extract 
produced better effects on osteoblast growth 
compared to the well established osteoporotic 
drug, pamidronate. Whereby, on day 7 until 
day 14, the ALP and osteocalcin levels were 
significantly higher in the QI treated group 
as compared to the other two control groups, 
including the pamidronate-treated group. 
Pamidronate belongs to a group of drugs called 
the bisphosphonates. The bisphosphonates are 
the most widely used drugs for the treatment of 
established primary and secondary osteoporosis 
(39). Although bisphosphonates are commonly 
used clinically to treat bone diseases, the 
mechanism of action of these compounds on 
bone is not completely understood. The effects of 
pamidronate on osteoblasts varies among studies. 
Ponader et al. (40), have found that pamidronate 
enhanced osteoblastic (hFOB) proliferation 
and differentiation, while Reinholz et al. (36), 
stated that the direct treatment of hFOB cells 
with pamidronate and zoledronate was found to 
decrease their cellolar cellular proliferation but 
enhanced cellular differentiation.
 In addition, Marolt et al. (41), observed that 
pamidronate treatment over extended periods 
could negatively affect bone balance by reducing 
ALP activity, cell proliferation and the viability 
of alveolar osteoblasts. In this current study, cell 
proliferation was increased in a time-dependent 
manner during pamidronate treatment, however, 
the hFOB cell numbers are lower compared 
to other groups (Figure 6). It can be assumed 
that hFOB cells proliferate better without the 
administration of pamidronate, and the possible 
reason may be due to the absence of pamidronate’s 
anabolic effects of on hFOB cells. 
 In a recent report, Lee and colleagues (2) 
found that ALP levels were significantly decreased 
after pamidronate treatments in children with low 
BMD during and after chemotherapy; however, 
no changes were observed in the levels of calcium, 
phosphate, magnesium, type I collagen c-terminal 
telopeptide (ICTP), and osteocalcin. Bauman 
et a1. (42), also demonstrated that osteocalcin 
levels displayed non-significant changes after 
adminstering pamidronate for more than 24 
months in patients with acute spinal cord injuries. 
On the other hand, previous observations 
suggested that pamidronate induced a significant 
increase in bone formation markers, bone alkaline 
phosphatase (BAP) and osteocalcin in patients 
with multiple myeloma (43). Moreover, Cauze et 
al. (44) reported that the efficacy of pamidronate 
treatment for postmenopausal osteoporosis was 
reflected in a decrease in circulating biochemical 
markers including ALP and osteocalcin. The 
results of these human studies suggest that 
the effects of pamidronate on bone formation 
markers vary according to the types of of disease, 
drug dosage, gender, and age. 
 To the best of our knowledge, the studies 
done regarding the effects of QI gall extract on 
bone metabolism are scarce. Hence, this research 
contributed more data on the positive role of QI 
gall extract on hFOB 1.19 cells. As mentioned in 
the literature review, QI gall extract contains 
many phytochemicals and minerals that are 
required in bone metabolism by enhancing the 
osteoblastic activity. Over a time course, these 
phytochemicals are believed to enhance the 
ALP activity, osteocalcin secretion, and calcium 
deposition (45). The ALP and osteocalcin are bone 
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formation markers for early-stage differentiated 
osteoblasts and terminally differentiated 
osteoblasts, respectively. As proven by the 
results of this study, QI gall extract stimulates 
the differentiation of hFOB 1.19 cells at various 
stages, starting from maturation to terminally 
differentiated osteoblasts. 
 Pertaining to the effect of QI gall extract 
on the morphology of hFOB 1.19, this study 
demonstrated that the extract promoted changes 
in osteoblast morphology by the increase of cell 
volume as well as by the maintenance of its flat 
and elongated shape. This result was consistent 
with another study using the alcoholic extract 
of Tinospora cordifolia (TC) where the cell 
morphology clearly showed an increase in cell 
numbers and the absence of adverse changes in 
cell morphology (46). However, these findings are 
still inadequate, and further studies are needed to 
provide more evidence on QI gall extract’s effects 
on the proliferation of hFOB 1.19 cells. 
Conclusion
 In summary, the proliferative effects of QI 
gall extract on hFOB 1.19 cells were better than 
pamidronate. Small concentrations of QI gall 
extract were able to enhance bone formation 
better compared to pamidronate. In addition, 
QI gall extract increased cell proliferation by 
increasing the level of bone formation markers 
(ALP and osteocalcin) secreted by the osteoblast 
cells. Thus, this study suggested that QI gall 
extract might be a potent anabolic agent that 
may significantly stimulate osteoblastic activity. 
Further studies are needed to confirm the efficacy 
of QI gall extract on hFOB 1.19 cells. In the future, 
we hope that QI gall extract will be developed as 
a safe and effective drug for the treatment and 
prevention of osteoporosis.
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